确诊或疑似遗传触发型胸主动脉夹层的血管内胸主动脉修复
研究分析GenTAC注册中31例确诊或疑似遗传触发型降胸主动脉夹层患者接受TEVAR的结果,围术期无死亡,中位随访2年,13例(41.9%)需再干预,急性B型夹层后逆行A型夹层风险高,慢性夹层相关动脉瘤样变者或可挽救不适合开放手术的高危患者。
要点
- TEVAR在遗传触发型主动脉夹层急性期可挽救生命,但急性B型夹层后逆行A型夹层风险高。
- 慢性夹层相关降胸主动脉瘤样变者,TEVAR对不适合开放手术的高危患者可能挽救生命。
- 术后需密切监测,因存在器械失败和再干预风险。
核心结论
- TEVAR在遗传触发型主动脉夹层急性期可挽救生命,但急性B型夹层后逆行主动脉夹层风险高。
- 慢性夹层相关降胸主动脉瘤样变者,TEVAR对不适合开放手术的高危患者可能挽救生命。
- 术后需密切监测,因存在后续器械失败和再干预风险。
- 由于这些情况罕见,多中心前瞻性入组遗传触发型主动脉疾病患者对明确TEVAR适应证和风险至关重要。
研究设计与样本
- 分析GenTAC注册中2006年至2014年降胸主动脉夹层接受TEVAR的患者数据。
- GenTAC入组确诊(综合征型或家族型)或疑似遗传触发型胸主动脉疾病患者,后者包括50岁及以下无家族史或综合征特征的散发性主动脉夹层患者。
- 共371例降胸主动脉夹层患者入组GenTAC,其中31例接受TEVAR(58.1%男性;中位年龄47岁;范围21.3-65.6岁)。
主要发现
- 31例TEVAR中,18例确诊遗传触发型主动脉夹层,另13例因早发表现疑似遗传触发型夹层。
- 9例A型主动脉夹层接受TEVAR:5例同期急性A型夹层修复,4例慢性期治疗残留降胸主动脉夹层动脉瘤样变(至TEVAR中位间隔2.1年)。
- 22例B型主动脉夹层接受TEVAR,12例急性、10例慢性(至TEVAR中位间隔1.6年)。
- 围术期无死亡;全部病例中位随访2年(范围0.4个月-7年)。
- TEVAR后再干预13例(41.9%),包括急性B型夹层TEVAR后3例逆行升主动脉夹层紧急修复(25%)和7例胸腹修复伴支架移植物取出(22.6%),中位7个月(范围1-16.6个月)。
临床怎么用
- 作者认为TEVAR在遗传触发型主动脉夹层急性期可挽救生命,但急性B型夹层后逆行主动脉夹层风险高。
- 作者认为慢性夹层相关降胸主动脉瘤样变者,TEVAR对不适合开放手术的高危患者可能挽救生命。
- 作者认为术后需密切监测,因存在后续器械失败和再干预风险。
- 作者认为需多中心前瞻性入组遗传触发型主动脉疾病患者以明确TEVAR适应证和风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endovascular repair in patients with connective tissues disorders is not recommended because of concern for repair failure. The aim of this study was to investigate thoracic endovascular aortic repair (TEVAR) outcomes in patients with confirmed or suspected syndromic and nonsyndromic genetically triggered thoracic aortic dissection. METHODS: We analyzed data for patients with descending thoracic aorta (DTA) dissection treated with TEVAR from the National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC). Enrolled patients had confirmed (syndromic or familial) or suspected genetically triggered thoracic aortic disease. The latter group includes patients with sporadic aortic dissection presenting at 50 years of age or younger in the absence of a family history or syndromic features. RESULTS: Between 2006 and 2014, there were 371 patients with DTA dissection enrolled in GenTAC. TEVAR was performed in 31 cases (58.1% male; median age, 47 years; range, 21.3-65.6 years). Genetically triggered aortic dissection was confirmed in 18 cases, and an additional 13 cases had suspected genetically triggered dissection because of early onset of presentation. TEVAR was performed in nine patients with type A aortic dissection: five in conjunction with acute type A dissection repair and four in the chronic phase to treat aneurysmal degeneration of the residual dissected DTA (median interval to TEVAR, 2.1 years). TEVAR was also performed in 22 cases of type B aortic dissection (TBAD), 12 acute and 10 chronic (median interval to TEVAR, 1.6 years). There were no perioperative deaths. Median follow-up for all cases was 2 years (range, 0.4 month-7 years). Reinterventions after TEVAR were performed in 13 cases (41.9%). This included urgent repair of three retrograde ascending aorta dissections occurring after TEVAR for acute TBAD (25%) and seven thoracoabdominal repairs with stent graft explantation (22.6%) at a median of 7 months after TEVAR (range, 1-16.6 months). CONCLUSIONS: TEVAR in patients with genetically triggered aortic dissections can be lifesaving in the acute setting though associated with high risk of retrograde aortic dissection in acute TBAD. For chronic dissection-related DTA aneurysmal degeneration, TEVAR could potentially be lifesaving in patients deemed too high risk for open surgical repair. Close postoperative surveillance is required, given the risk of subsequent device failure and need for reintervention. Because these circumstances are rare, multicenter prospective enrollment of patients with genetically triggered aortic disease is essential to delineate the indications for and risks of TEVAR in this heterogeneous population.
引用
- Shalhub S, Eagle KA, Asch FM, et al. Endovascular thoracic aortic repair in confirmed or suspected genetically triggered thoracic aortic dissection. J Vasc Surg. 2018. PMID: 29567025. doi:10.1016/j.jvs.2017.11.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。